Uncategorized
Fenofibrate slows diabetic retinopathy progression in at-risk patients
Intensive treatment of glycemia and dyslipidemia slowed the progression of diabetic retinopathy in diabetic patients with cardiovascular disease or associated risk factors, according to study findings.Data were culled from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, a collection of three randomized clinical trials designed to evaluate the effects of intensive blood glucose and blood pressure control and a combination of fenofibrate and statin vs. statin monotherapy therapy for dyslipidemia on the incidence of cardiovascular disease in patients with type 2 diabetes.